A global comparison of the cost of patented cancer drugs in relation to global differences in wealth

Abstract

Cancer drugs are less affordable in middle-income countries than in high-income countries. Differential pricing may be an acceptable policy to ensure global affordability and access to highly active anti-cancer therapies.